Meeting
2015 Genitourinary Cancers Symposium
Phase II clinical trial of low-dose interleukin-2, interferon-alpha, and low-dose tegafur uracil therapy for advanced renal cell cancer.
Authors
Tomoyuki Kato
Department of Urology, Yamagata University Faculty of Medicine, Yamagata, Japan
Tomoyuki Kato , Masatsugu Iwamura , Tetsuo Fujita , Seiichi Saito , Yoshinori Ohshiro , Tomoyuki Imai , Nozomu Kawata , Yoshihiko Tomita , Takehiro Sejima , Takeshi Kishida , Tatsuo Tochigi , Sadafumi Kawamura
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session C: Renal Cancer
Track
Renal Cell Cancer
Sub Track
Renal Cell Cancer
Clinical Trial Registration Number
00002222
Citation
J Clin Oncol 33, 2015 (suppl 7; abstr 508)
DOI
10.1200/jco.2015.33.7_suppl.508
Abstract #
508
Poster Bd #
H20
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
High-dose interleukin-2 (HD IL-2) in the treatment of advanced melanoma: The University of Pittsburgh experience.
First Author: Diwakar Davar
Poster
2023 ASCO Annual Meeting
CASSIOPE: A prospective noninterventional study of cabozantinib treatment following prior vascular endothelial growth factor (VEGF) -targeted therapy in patients with advanced renal cell carcinoma (aRCC).
First Author: Michael D. Staehler
Poster
2023 ASCO Annual Meeting
Nipavect: Phase II study of niraparib and panitumumab in advanced RAS WT colorectal cancer.
First Author: Olatunji B. Alese
Poster
2022 ASCO Annual Meeting
Trial in progress: A phase 1-2, first-in-human, open label, dose escalation and expansion study of AU-007, a monoclonal antibody that binds to IL-2 and inhibits IL-2Rα binding, in patients with advanced solid tumors.
First Author: James Robert Vasselli